DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2021 của Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is … More a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function.

TÊN CÔNG TY / COMPANY
Immunic, Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
IMUX

KỲ BÁO CÁO
2021

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare